This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Aclarubicin
- DrugBank Accession Number
- DB11617
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Aclarubicin (DB11617)
- Weight
- Average: 811.878
Monoisotopic: 811.341520011 - Chemical Formula
- C42H53NO15
- Synonyms
- Aclacinomycin A
- Aclarubicin
- aclarubicina
- External IDs
- NSC-208734
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareArticaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Cocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Aclarubicin hydrochloride 501948RI66 75443-99-1 KUSMIBXCRZTVML-PCCPLWKKSA-N
Categories
- ATC Codes
- L01DB04 — Aclarubicin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Anthracyclines
- Sub Class
- Not Available
- Direct Parent
- Anthracyclines
- Alternative Parents
- Tetracenequinones / Aminoglycosides / Anthracenecarboxylic acids / Anthraquinones / Naphthalenecarboxylic acids and derivatives / Disaccharides / O-glycosyl compounds / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids show 16 more
- Substituents
- 1,4-anthraquinone / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 1-naphthalenecarboxylic acid or derivatives / 9,10-anthraquinone / Acetal / Alcohol / Amine / Amino acid or derivatives / Amino saccharide show 37 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- phenols, trisaccharide derivative, methyl ester, polyketide, aminoglycoside, anthracycline, tetracenequinones (CHEBI:74619)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 74KXF8I502
- CAS number
- 57576-44-0
- InChI Key
- USZYSDMBJDPRIF-SVEJIMAYSA-N
- InChI
- InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
- IUPAC Name
- methyl (1R,2R,4S)-4-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-{[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
- SMILES
- CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=C(C(O)=CC=C1)C3=O
References
- General References
- Jensen PB, Jensen PS, Demant EJ, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O, Hansen HH: Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 1991 Oct 1;51(19):5093-9. [Article]
- Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J: Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921. [Article]
- Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J: Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol. 2015 Jul;11(7):472-80. doi: 10.1038/nchembio.1811. Epub 2015 May 11. [Article]
- External Links
- KEGG Drug
- D02756
- KEGG Compound
- C18638
- PubChem Compound
- 451415
- PubChem Substance
- 347828010
- ChemSpider
- 397638
- BindingDB
- 50368351
- 239
- ChEBI
- 74619
- ChEMBL
- CHEMBL502620
- ZINC
- ZINC000085537142
- Wikipedia
- Aclarubicin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Acute Myeloid Leukemia 3 3 Unknown Status Treatment Acute Myeloid Leukemia / Induction chemotherapy 1 2 Not Yet Recruiting Treatment Acute Myeloid Leukemia / Elderly Patients / Newly Diagnosed 1 2 Unknown Status Treatment Acute Myeloid Leukemia 1 2 Unknown Status Treatment Acute Myeloid Leukemia / Relapsed Leukemia 1 1 Completed Treatment Cerebroretinal Vasculopathy, Hereditary / Vasculopathy, Retinal, With Cerebral Leukodystrophy 1 Not Available Recruiting Treatment Acute Myeloid Leukemia 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.218 mg/mL ALOGPS logP 2.79 ALOGPS logP 3.98 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 7.47 Chemaxon pKa (Strongest Basic) 8.64 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 217.05 Å2 Chemaxon Rotatable Bond Count 10 Chemaxon Refractivity 203.87 m3·mol-1 Chemaxon Polarizability 84.31 Å3 Chemaxon Number of Rings 7 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at August 25, 2016 23:13 / Updated at February 21, 2021 18:53